Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Celldex Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
6.79
12.7
9.54
3.57
7.42
4.65
2.36
6.88
7.02
1.55
Cost of revenue
1.6
0.7
0.7
0.1
0.2
0.1
0.1
0.3
0.2
0.2
Gross profit
5.19
12
8.84
3.47
7.22
4.55
2.26
6.58
6.82
1.35
Research and development
103
96.2
66.4
42.7
42.5
53.3
82.3
118
164
245
General and administrative
36
25
19.3
15.4
14.5
20.5
27.2
30.9
38.5
43.8
Operating income
-133
-122
-156
-55
-63.4
-71.2
-115
-155
-195
-287
Pre-tax income
-129
-117
-152
-50.9
-60.9
-70.7
-112
-141
-158
-259
Income tax
-24.3
-0.77
-1.17
-0.23
0
0
0
Net income
-129
-93
-151
-50.9
-59.8
-70.5
-112
-141
-158
-259
EBITDA
-130
-117
-153
-50.2
-59.4
-68.2
-112
-152
-192
-284
EPS, basic
-18.99
-10.86
-14.48
-3.51
-2.02
-1.64
-2.40
-2.92
-2.45
-3.90
EPS, diluted
-18.99
-10.86
-14.48
-3.51
-2.02
-1.64
-2.40
-2.92
-2.45
-3.90
Shares, basic (weighted)
6.77
8.57
0.01
0.01
0.03
0.04
0.05
48.4
64.4
66.4
Shares, diluted (weighted)
6.77
8.57
0.01
0.01
0.03
0.04
0.05
48.4
64.4
66.4
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
42.5
40.3
24.3
11.2
43.8
39.1
29.4
34.8
28.4
28.9
Short-term investments
147
99.1
69.7
53.2
151
369
276
389
697
490
Other current assets
4.01
3.45
1.9
1.3
1.62
2.42
12.4
5.47
21.2
14.1
Total current assets
196
145
99.1
66.7
198
411
318
432
747
535
Property, plant and equipment
13.2
10.4
6.11
4.03
3.82
3.55
3.75
4.06
4.35
5.33
Lease right-of-use assets
3.47
3.45
2.97
4
2.58
3.9
2.44
Goodwill
91
91
Intangible assets
81.5
67.6
48.7
48.7
30.7
27.2
27.2
27.2
27.2
27.2
Other non-current assets
2.13
1.93
1.93
0.04
0.04
0.1
0.1
0.11
9.75
13.4
Total assets
383
316
156
123
236
445
353
466
792
583
Accounts payable
1.74
1.72
1.07
1.17
1.05
1.23
3.34
3.49
3.27
1.18
Accrued liabilities
28.7
19.5
7.01
6.5
8.46
12
12.8
22
33.8
47
Total current liabilities
35.2
27.7
12.6
11.6
14.2
16.5
18.6
31.1
39.5
51
Lease liabilities
1.71
2.15
1.3
2.59
0.93
2.36
0.78
Other non-current liabilities
82.7
51.5
19.1
15.6
10.1
7.35
5.33
4.4
3.47
4.04
Total liabilities
118
79.3
31.7
28.9
26.5
25.2
26.5
36.5
45.3
55.8
Paid-in capital
982
1,046
1,084
1,105
1,280
1,561
1,581
1,823
2,299
2,337
Retained earnings
-719
-813
-962
-1,013
-1,073
-1,144
-1,256
-1,397
-1,555
-1,814
Other comprehensive income
2.54
2.56
2.58
2.62
2.59
1.89
1.26
3.31
3.31
3.63
Shareholders' equity
265
236
124
94
209
419
326
429
747
527
Total equity
265
236
124
94
209
419
326
429
747
527
Total liabilities and equity
383
316
156
123
236
445
353
466
792
583
Shares outstanding
121
9.23
12
17
39.6
46.7
47.2
55.9
66.4
66.5
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-129
-93
-151
-50.9
-59.8
-70.5
-112
-141
-158
-259
Depreciation and amortization
3.1
4.41
3.58
4.86
3.93
3.07
2.9
3.01
3.18
3.38
Stock-based compensation
15.3
12.3
8.08
4.55
3.92
8.95
15.6
23.9
34.2
36.2
Change in payables
-4.97
-8.74
-13.1
-0.32
1.64
3.65
3.12
9.38
11.6
11
Cash from operations
-113
-99.9
-75.2
-46.4
-40.4
-60.9
-104
-107
-158
-211
Capital expenditures
-2.75
-1.79
-0.81
-0.73
-1.55
-1.25
-1.83
-1.82
-1.92
-2.71
Purchases of investments
-174
-171
-171
-95.4
-220
-390
-189
-425
-790
-385
Sales and maturities of investments
243
219
201
113
124
175
281
321
502
596
Cash from investing
68.9
46.5
29.8
17.1
-98.2
-216
89.9
-106
-290
209
Debt issued
2.96
Debt repaid
-2.96
Stock issued
13.9
51
29
16.2
171
270
216
432
Cash from financing
14.5
51.3
29.4
16.3
171
272
4.08
218
441
2.39
Net change in cash
-29.6
-2.17
-16
-13.1
32.6
-4.69
-9.71
5.39
-6.46
0.52
Free cash flow
-116
-102
-76
-47.1
-42
-62.2
-106
-109
-160
-214
Income taxes paid
0
0
0
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $31.10 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-206,221.0%
Operating income / revenue.
EBITDA margin
-204,072.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-190,221.0%
Net income / revenue.
FCF margin
-153,231.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-149,092.0%
Cash from operations / revenue.
Return on equity (ROE)
-42.1%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-38.4%
Net income / average total assets.
Return on invested capital (ROIC)
-38.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
176,460.0%
Research and development expense / revenue.
Stock-based pay / revenue
21,925.0%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
4,139.0%
Capital expenditures / revenue.
D&A / revenue
2,149.0%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
-78.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
-13.1%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
-26.9%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
-80.3%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
-15.8%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
-28.5%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-29.4%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
17.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
20.3%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-26.4%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
18.2%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
19.8%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
3.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
1,023.0%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
367.8%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
11.8x
Current assets / current liabilities.
Quick ratio
11.7x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
11.7x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.00
Revenue / diluted weighted shares.
FCF per share
-$3.11
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$3.03
Cash from operations / diluted weighted shares.
Book value per share
$9.10
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
15,457x
Market cap / revenue.
P/B
3.42x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.55x
Market cap / tangible book value, when positive.
EV/Sales
10,916x
Enterprise value / revenue.
FCF yield
-9.9%
Free cash flow / market cap.
Earnings yield
-12.3%
Net income / market cap (the inverse of P/E).
What was Celldex Therapeutics, Inc.'s revenue in fiscal 2025?
Celldex Therapeutics, Inc. reported revenue of $1.5M for fiscal 2025, 78% lower than the year before.
Was Celldex Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $258.8M.
How much free cash flow did Celldex Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $210.9M minus capital expenditures of $2.7M left free cash flow of -$213.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.